(Q30413154)

21 June 2017

Peramivir for the treatment of influenza (English)

1 reference

21 June 2017

Avinash K Shetty

1

0 references

author name string

Leigh A Peek

series ordinal

2

1 reference

21 June 2017

1 February 2012

1 reference

Expert Review of Anti-infective Therapy

21 June 2017

1 reference

21 June 2017

10

1 reference

21 June 2017

2

1 reference

21 June 2017

123-143

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

21 June 2017

1 reference

A review of vaccine research and development: human acute respiratory infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Pandemic influenza's 500th anniversary

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Influenza vaccines for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

The influenza virus enigma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Developing new antiviral agents for influenza treatment: what does the future hold?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Neuraminidase inhibitors for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

The origin and global emergence of adamantane resistant A/H3N2 influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Stereoselective total synthesis of racemic BCX-1812 (RWJ-270201) for the development of neuraminidase inhibitors as anti-influenza agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Anti-influenza virus activity of peramivir in mice with single intramuscular injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Peramivir and its use in H1N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Evaluation of methyl inosine monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Peramivir clearance in continuous renal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Critically ill patients with 2009 influenza A(H1N1) infection in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

In vitro and in vivo assay systems for study of influenza virus inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Safety and pharmacology of oseltamivir in clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Postpartum pharmacokinetics of peramivir in the treatment of 2009 H1N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

The emergency use authorization of peramivir IV: a view from the manufacturer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Systematic review of influenza resistance to the neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Global transmission of oseltamivir-resistant influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Targeting pandemic influenza: a primer on influenza antivirals and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Detection of oseltamivir resistance during treatment of 2009 H1N1 influenza virus infection in immunocompromised patients: utility of cycle threshold values of qualitative real-time reverse transcriptase PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

H1N1 pneumonitis treated with intravenous zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Complexity in influenza virus targeted drug design: interaction with human sialidases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Current and future antiviral therapy of severe seasonal and avian influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Drugs in development for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Influenza pharmacotherapy: present situation, strategies and hopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Outcomes of adults hospitalised with severe influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Severe 2009 H1N1 Influenza in Pregnant and Postpartum Women in California

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Severe, critical and fatal cases of 2009 H1N1 influenza in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Losing the opportunity to study influenza drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Pandemic (H1N1) 2009-associated ARDS rescued by neuraminidase inhibitors with emergency use of extracorporeal membrane oxygenation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Successful salvage therapy with inhaled zanamivir in a patient with peramivir-resistant pandemic influenza A (H1N1) 2009 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Use of intravenous neuraminidase inhibitors during the 2009 pandemic: results from population-based surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Oseltamivir for treatment and prophylaxis of influenza infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

Antiviral drugs underused in US patients for 2009 influenza A(H1N1) pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.174

21 January 2018

Identifiers

DOI

10.1586/ERI.11.174

1 reference

21 June 2017

1 reference

PubMed ID

22339187